Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03678883 · ClinicalTrials.gov registry record · Phase 2
9-ING-41 in Patients with Advanced Cancers
A Phase 2 study of Cancer and Pancreatic Cancer, sponsored by Actuate Therapeutics.
- Active
- Registry status
- Phase 2
- Development phase
- 350
- Enrollment target
- 20
- Study locations
NCT03678883 is a Phase 2 study of Cancer and Pancreatic Cancer that is active but no longer recruiting, run by Actuate Therapeutics. The registered enrollment target is 350 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (90% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT03678883, a Phase 2 study of Cancer and Pancreatic Cancer, is active but no longer recruiting, sponsored by Actuate Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 350 participants
- Enrollment target
- 20
- Study locations
Study Summary
GSK-3β is a potentially important therapeutic target in human malignancies. The Actuate 1801 Phase 1/2 study is designed to evaluate the safety and efficacy of 9-ING-41, a potent GSK-3β inhibitor, as a single agent and in combination with cytotoxic agents, in patients with refractory cancers.
Conditions Studied
Interventions
- DRUG Lomustine
- DRUG 9-ING-41
- DRUG Gemcitabine - 21 day cycle
- DRUG Doxorubicin.
- DRUG Carboplatin.
Study Locations (20)
Arizona
- Mayo Clinic - Phoenix
- Arizona Oncology Associates - Tucson
- The University of Arizona Cancer Center - Tucson
Florida
- Florida Cancer Specialists - South - Fort Myers
- Miami Cancer Institute - Miami
- Florida Cancer Specialists - North - St. Petersburg
California
- University of California Irvine Health - Orange
- UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco
Minnesota
- MetroMetro-Minnesota Community Oncology Research Consortium (MMCORC) - Minneapolis
- Mayo Clinic - Rochester
New Jersey
- Morristown Medical Center - Morristown
- Capital Health Medical Center/ Hopewell - Pennington
Delaware
- Christiana Care Health Services - Newark
District of Columbia
- Sibley Memorial Hospital - Washington D.C.
Illinois
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2019-01-04 |
| Est. Completion | 2026-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03678883
The ClinicalTrials.gov registry entry for NCT03678883 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 350 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (90% lower). The listed sponsor is Actuate Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Cancer appearing as the primary indexed condition, and to 5 interventions - of which Lomustine is the first listed.
NCT03678883 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Arizona, Florida, California.
Frequently Asked Questions
What is clinical trial NCT03678883 about?
NCT03678883 is a clinical study titled "9-ING-41 in Patients with Advanced Cancers". GSK-3β is a potentially important therapeutic target in human malignancies. The Actuate 1801 Phase 1/2 study is designed to evaluate the safety and efficacy of 9-ING-41, a potent GSK-3β inhibitor, as a single agent and in combination with cytotoxic agents, in patients with refractory cancers.
What is the current status of trial NCT03678883?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 350 participants. The study started on 2019-01-04. Estimated completion is 2026-01.
What conditions does trial NCT03678883 study?
This clinical trial studies the following conditions: Cancer, Pancreatic Cancer, Sarcoma, Pancreatic Adenocarcinoma, Neoplasm Metastasis.
What interventions are being tested in trial NCT03678883?
The interventions under investigation include: Lomustine (DRUG), 9-ING-41 (DRUG), Gemcitabine - 21 day cycle (DRUG), Doxorubicin. (DRUG), Carboplatin. (DRUG).
Who is sponsoring clinical trial NCT03678883?
This trial is sponsored by Actuate Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03678883 being conducted?
This trial has 20 study locations across Arizona, California, Delaware, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
RECRUITING · Phase 2
-
TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors
RECRUITING · Phase 2
-
CAncer TReatment INformed by the Molecular Tumor Board At Dartmouth
RECRUITING · Phase 2
-
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
Acupuncture for People Experiencing Period Loss Due to Chemotherapy
RECRUITING · Phase 2
-
Improving Cancer-related Fatigue, Sexual Dysfunction and Quality of Life in Older Men With Cancer and Androgen Deficiency
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.